L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
NEW YORK, Nov. 14, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”) has filed an action in the United States District Court – Western District of Kentucky against Humana, Inc. and Humana Pharmacy Solutions, Inc. (collectively, “Humana” or “Defendants”).
Defendants are health insurance companies along with pharmacy benefit managers (“PBMs”). The PBMs are retained by the health insurance companies, on behalf of the plan or third-party payors, to provide the pharmacy benefits to plan members, which includes, inter alia, establishing a formulary of drugs that will be covered, a network of pharmacies that will serve as participating pharmacies for plan participants to obtain their prescriptions, copayment amounts, coinsurance amounts, and deductibles.
Specifically, the action relates to Defendants engaging in a scheme to defraud plan members by artificially inflating the copayment of medically necessary prescription drugs well above the cost of the drug. Plan participants, including Plaintiff and the Class, pay inflated copayments to participating pharmacies in exchange for receiving their prescription drugs. Unbeknownst to the plan participants, Defendants artificially inflate the purported costs of the prescription drugs in the form of increased copayments and then “claw back,” or recoup, from the pharmacies a large portion of the copayments.
Class members are consumers who pay artificially inflated copayments for medically necessary, covered prescriptions that cost plan participants more than if they did not have insurance. If you would like addition information, please contact Michael Burnett of Scott+Scott ([email protected], (800) 404-7770, (860) 537-5537).
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide.
CONTACT: Michael Burnett Scott+Scott, Attorneys at Law, LLP (800) 404-7770 [email protected]
